ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

about

ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

Item

http://www.wikidata.org/entity/Q47103348

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

@en

ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

@nl

type

Item

label

ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

@en

ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

@nl

prefLabel

ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

@en

ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

@nl

P1476

ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.

@en

P2093

Bowen Wan

http://www.w3.org/2001/XMLSchema#string

Gang Yin

http://www.w3.org/2001/XMLSchema#string

Guoyong Yin

http://www.w3.org/2001/XMLSchema#string

Hao Zhou

http://www.w3.org/2001/XMLSchema#string

Jin Fan

http://www.w3.org/2001/XMLSchema#string

Jun Zhang

http://www.w3.org/2001/XMLSchema#string

Pengyu Tang

http://www.w3.org/2001/XMLSchema#string

Qingfeng Ding

http://www.w3.org/2001/XMLSchema#string

Wei Zhou

http://www.w3.org/2001/XMLSchema#string

Xuan Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

mTOR kinase inhibitors as potential cancer therapeutic drugs

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Salinomycin activates AMP-activated protein kinase-dependent autophagy in cultured osteoblastoma cells: a negative regulator against cell apoptosis

mTOR and cancer: insights into a complex relationship

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).

mTOR inhibitors in cancer therapy.

P304

82027-82036

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18303

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29137241

http://www.w3.org/2001/XMLSchema#string

P932

5669867

http://www.w3.org/2001/XMLSchema#string